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Abstract
Background: Cerebral malaria (CM) is an acute encephalopathy with increased pro-inflammatory
cytokines, sequestration of parasitized erythrocytes and localized ischaemia. In children CM
induces cognitive impairment in about 10% of the survivors. Erythropoietin (Epo) has – besides of
its well known haematopoietic properties – significant anti-inflammatory, antioxidant and anti-
apoptotic effects in various brain disorders. The neurobiological responses to exogenously injected
Epo during murine CM were examined.
Methods: Female C57BL/6j mice (4–6 weeks), infected with Plasmodium berghei ANKA, were
treated with recombinant human Epo (rhEpo; 50–5000 U/kg/OD, i.p.) at different time points. The
effect on survival was measured. Brain pathology was investigated by TUNEL (Terminal
deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-digoxigenin nick
end labelling), as a marker of apoptosis. Gene expression in brain tissue was measured by real time
PCR.
Results: Treatment with rhEpo increased survival in mice with CM in a dose- and time-dependent
manner and reduced apoptotic cell death of neurons as well as the expression of pro-inflammatory
cytokines in the brain. This neuroprotective effect appeared to be independent of the
haematopoietic effect.
Conclusion: These results and its excellent safety profile in humans makes rhEpo a potential
candidate for adjunct treatment of CM.
Background
Plasmodium falciparum malaria remains a massive burden
of disease with an estimated two million deaths world-
wide each year [1] mainly due to the two major complica-
tions, cerebral malaria (CM) and severe anaemia.
Moreover long-term neurological sequelae in 2–11% of
the survivors of CM are increasingly recognized [2-4]. CM
is an acute – and potentially reversible – encephalopathy
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with increased serum-levels of pro-inflammatory
cytokines such as tumor necrosis factor (TNF), interferon-
γ (IFN-γ), and lymphotoxin (LT) [5,6]. Post-mortem
examination of the brain reveals haemorrhages, oedema
and adherence of parasitized red blood cells (pRBC) to
the cerebral microvasculature. Although CM has been
studied extensively, many of the pathophysiological
mechanisms remain unclear and highly effective treat-
ment other than antiparasitic medication is not available.
A number of adjunct therapies have been proposed for
CM including dexamethasone, hyperimmune serum,
anti-TNF antibody, pentoxyfylline, osmotic diuretics,
heparin, anti-convulsants and red blood cell (RBC)
exchange transfusion, each based on a different patho-
physiological rationale. Only anti-convulsants and to a
lesser extend RBC exchange transfusion have shown to be
partially effective [4].
Erythropoietin (Epo) was first identified as an haemat-
opoietic growth factor produced in the kidneys, and
recombinant human Epo (rhEpo) is widely used to treat
anaemia [7]. Increased serum Epo levels promote survival
of erythroid precursor cells of the bone marrow that
would otherwise undergo apoptosis [8]. The observation
that Epo and its receptor are expressed in practically all
brain cells expanded the biological role of Epo beyond
haematopoiesis (reviewed in [9,10]).
In vitro studies have shown that Epo protects neurons
against ischaemic damage by reducing apoptosis [11], but
the cytoprotective effects are not restricted to neurons:
Epo can also protect endothelial cells [12] and glial cells
[13]. Apart from its anti-apoptotic effect, Epo may
reduced astrocyte activation [14], cause direct neuro-
trophic effects [15], act as antioxidant [16] and stimulate
angiogenesis [17].
Subsequent in vivo studies of systemic treatment with
rhEpo reported a reduction of neuronal damage and neu-
rological dysfunction in rodent models after stroke [18-
20], mechanical trauma, excitotoxic injury and experi-
mental autoimmune encephalitis (EAE) [21]. Strikingly, a
recent study in a mouse model of CM showed an increase
of survival in rhEpo-treated animals [22]. Moreover, a
proof-of-concept trial in human patients with ischaemic
stroke has shown a neuroprotective effect of high-dose
rhEpo within six hours after onset of symptoms [23].
Considering these preclinical and clinical data, rhEPO is
an attractive potential candidate for the therapy of CM.
The aims of the present study were explore the effect of
systemic administered rhEpo in an animal model of CM,
and thereby to contribute to the body of evidence that can
build the basis for a treatment of human CM patients.
Experimental models cannot reproduce all the features of
human diseases, and this is true for CM. One major differ-
ence from the human disease is that mice do not develop
high fevers but instead develop a progressive hypothermia
in the days prior to death what is best explained by the big
surface area of the mice relative to their size, leading to a
heat loss in severe diseased animals. The model used for
this study shows however main features also seen in
human CM: A clinical picture including coma, seizures
and neurological impairment, strong histopathological
similarities with impairment of the BBB and petechial
bleedings and a systemic as well as a local immune
responses having TNF, INF-γ and Il-1β strongly involved
as pro-inflammatory cytokines [6,24,25]. The use of
rodent malaria parasites in mice is therefore widely
accepted as the model of choice for studying the patho-
genesis of CM [6,24].
Methods
Animals
Female pathogen-free C57BL/6j mice 4–6 weeks old,
weighing 18–22 g, were purchased form Taconic, Den-
mark. A total of 199 mice, 149 for the survival studies was
used, 30 for gene expression analysis and 20 for embed-
ding of the brains and staining. The results were obtained
from three independent experiments. All animals were
pathogen-free and were kept under standard conditions,
with ad libitum access to food and water. All experiments
adhered to Danish and European guidelines for animal
research and were approved by the national board for ani-
mal studies. All efforts were made to minimize animal suf-
fering and to reduce the number of animals used. The
development of ECM is accompanied by a severe drop of
body temperature. Mice with a body temperature below
32°C do not recover. Body temperature below 32°C as a
proxy for death.
Induction of ECM
Mice were infected on day 0 with Plasmodium berghei
ANKA parasites by intraperitoneal inoculation with 104
parasitized red blood cells (pRBC) from mice of the same
strain, diluted in normal saline. Parasitaemia was deter-
mined using Giemsa-stained thin blood films. The ani-
mals were under daily supervision for clinical signs of
disease, body temperature and neurological symptoms.
ECM was diagnosed by clinical signs including ataxia,
paralysis (mono, hemi, para, or tetraplegia), deviation of
the head, convulsions, and coma. Body temperature was
measured rectally once or twice a day (Digital thermome-
ter DM852 with rectal probe, Ellab, Denmark).
Mice were treated with erythropoietin alpha, i.p. (Eprex,
Janssen-Cilag, Schaffhausen, Switzerland) diluted in NaCl
(0.9%) in various dosages (1–200 U daily i.p. diluted in
0,2 ml normal saline per injection) and different treat-Malaria Journal 2008, 7:3 http://www.malariajournal.com/content/7/1/3
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ment schemes. Infected control mice were treated with
NaCl (0.9%) only. For immunohistochemistry and rt-
PCR analysis of the brains animals were killed on day 8.
Survival studies were terminated by killing animals, whith
body temperature below 32°C. Surviving animals were
killed on day 15 post-inoculation.
Tissue processing and in situ detection of DNA 
fragmentation
Tissue processing was performed according to standard
procedures, as described elsewhere [26]embedded in par-
affin, and cut in serial 5 μm-thick sections. Terminal deox-
ynucleotidyl transferase (TdT)-mediated deoxyuridine
triphosphate (dUTP)-digoxigenin nick end labelling
(TUNEL) staining was performed according to manufac-
turers' protocol using the TdT-FragEL DNA Fragmentation
Detection Kit (Oncogene Research Products, Cambridge,
UK; code Cat# QIA 33). DAB was used as chromogen and
the sections were counterstained with methyl green.
Visualisation and counts
Sections were examined on an Imager.Z1 microscope with
an AxioCam MRc5 camera (Carl Zeiss, Germany). Images
were processed using Adobe Photoshop CS (Adobe, USA).
In addition to morphological analysis, cellular counting
was carried out in a blinded and randomized manner by
a single investigator. TUNEL+ cells were counted in sagit-
tal sections from close to the midline of the brain, using
one section from each hemisphere.
Measuring of packed cell volume (PCV)
Tail blood or blood from the retro orbital venous plexus
was sampled in EDTA coated capillary tubes (20 μl, Bie
and Berntsen, Denmark) and analysed on an automated
analyser (KX-21N, Sysmex, USA).
Gene expression
For quantitative PCR, separate groups of mice (n = 27)
were either infected as described above and treated with
rhEpo (100 U i.p. on day 1,4 and 7 post-inoculation) or
vehicle or left uninfected. Mice were perfused trans-car-
dially with NaCl (0.9%) with 0.3% heparin (15,000 IU/L)
for 30 – 60 seconds. Brains were removed, parted into
right and left cerebrum and cerebellum and immediately
frozen in liquid nitrogen.
RNA was isolated from homogenized tissue using a stand-
ard RNeasy lipid tissue kit (Qiagen, USA) according to the
manufacturers' protocol followed by dilution in first Qia-
zol lysis reagent (Qiagen, USA) and secondly chloroform
99.9% (Sigma, Denmark) to separate phases.
Quantification of RNA content was done by using the
Rediplate Ribogreen kit (Invitrogen, USA) and cDNA was
synthesized using the QuantiTect Reverse Transcription
Kit (Qiagen, USA).
All real time-PCR reactions were carried out on a MX-
3000p (Stratagene, USA) and run for 50 cycles using the
QuantiTect Probe PCR Kit (Qiagen, USA) according to the
manufacturers protocol and the following protein specific
kits: β-actin, cat. no. 241014, caspase 3, cat. no. 241124,
no. 241054, caspase 1, cat. no. 241151, TNF, cat. no.
241034, IFN-γ, cat. no. 241036, IL-1β, cat. and LT: cat no.
241174. Cycle-threshold (Ct) values were defined as the
PCR cycle at which amplified product was first detected.
Gene-expression levels were assessed by the comparative
threshold method, using expression of the β-actin gene as
reference.
Statistical analysis
Results for multiple groups were evaluated by ANOVA
using the Holm-Sidak method for multiple comparisons.
Student's-t test were used when comparing two groups
and by log-rank statistic for the survival curves with pair
wise comparison using the Holm-Sidak method. For rt-
PCR data student's-t-test was applied on Ct-values. Cox
regression for survival analysis was performed using sur-
vival as dependent variable and treatment, parasite level
on day 8 and PCV on day 8 as covariates. The heights of
the columns represent mean values. Raw data were proc-
essed by log- or ln-transformation to improve the homo-
geneity of variances where necessary. A difference was
considered significant for P-values <0.05. Box plot graphs
show the percentiles and the median. Cox regression anal-
ysis for survival was performed using the SPSS 11.5 soft-
ware package (SPSS Inc., USA) otherwise were the data
analysed using the SigmaPlot 9.01 software package (Sys-
tat Software, Inc, USA).
Results
Treatment with rhEpo resulted in an increased survival of
mice with cerebral malaria in a dose dependent manner.
The highest increase in survival was achieved, when mice
were treated from day 4 to day 7 post-inoculation with
either 200 U, 100 U or 50 U once daily (Figure 1). 56%,
48% and 45% respectively survived until day 14, com-
pared to the saline treated group, where no animal sur-
vived longer than day 11 (p <0.001 for the two former
groups and p = 0.001 for the latter group, all vs. saline
treated controls). No significant difference was seen
between the three groups. A lower dose of 25 U rhEpo
given daily from day 4–7 resulted in 30% percent survival
on day 14 (p = 0.001 vs. saline treated controls), while 1
U and 10 U rhEpo daily did not increase survival signifi-
cantly.
RhEpo treatment on day 4–7 increased packed cell vol-
ume (PCV) levels measured on day 8 (before killing),Malaria Journal 2008, 7:3 http://www.malariajournal.com/content/7/1/3
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compared to saline-treated controls: The lowest dose of 1
U/day of rhEpo increased the PCV from 44.2% (saline-
treated, infected controls) to 51.0% and 10 U/day resulted
in a PCV level of 58.4%, while higher doses of 25–200 U/
day not further increased PCV levels significantly
(Figure 2).
The effect of the treatment on the time and duration of
rhEpo administration: 100 U rhEpo daily was able to
increase survival only when administered on day 4–7 (as
described above). Early treatment on day 1–4 and late
treatment on day 7–10 did not increase survival. Surpris-
ingly, also animals treated for a longer period from day 1–
7 with 100 U daily failed to show increased survival.
Those animals reached a mean packed cell volume (PCV)
of 73% on day 8. In order to eliminate a possible negative
effect of the high PCV a group of animals likewise treated
on day 1–7 with 100 U rhEpo daily were bled for about
10% of their total blood volume on day 5, resulting in a
mean PCV level of 58.6%, which is similar to animals that
received treatment only on day 4–7. Despite that, survival
was not increased significantly (Figure 3).
Mean parasitaemia levels on day 8 ranged from 6.3 –
12.6% pRBC (Figure 4). The difference was significant
only between animals that had received 25 U/day on day
4–7 and saline treated controls (P < 0.05). The differences
between all other groups were not significant. Cox regres-
sion analysis to explore the effects of different variables on
survival and testing for the covariates treatment, parasitae-
mia on day 8 and PCV on day 8 showed that only treat-
ment was correlated with increased survival (P < 0.001)
Packed cell volume in recombinant human erythropoietin- treated and untreated mice with cerebral malaria Figure 2
Packed cell volume in recombinant human erythro-
poietin-treated and untreated mice with cerebral 
malaria. Packed cell volume (PCV) measured on day 8 in 
animals treated on day 4–7 or 1–7 respectively and vehicle 
treated controls: Treatment with recombinant human eryth-
ropoietin (rhEpo) increases PCV levels in mice with cerebral 
malaria. 1 U daily from day 4–7 increases the PCV to 51% 
while 10 U or more daily given on day 4–7 lead to mean PCV 
levels between 58.4% and 59.7%. PCV levels in the group 
treated on day 1–7 with 100 U daily reached very high values 
of 73.0% unless these mice where bled for 10% of their total 
blood volume on day 5. This intervention reduced the mean 
PCV level to 58.6% (right plot). P < 0.001. Statistical test: 
One way ANOVA. The ends of the boxes define the 25th 
and 75th percentiles, with a line at the median and error bars 
defining the 10th and 90th percentiles.
Dose depandant increase in survival in recombinant human  Erythropoietin-treated mice with cerebral malaria Figure 1
Dose depandant increase in survival in recombinant 
human Erythropoietin-treated mice with cerebral 
malaria. Dose dependant increase in survival in recom-
binant human erythropoietin-treated mice with CM: Cumula-
tive survival analysis of mice ECM treated with rhEpo from 
day 4–7 in different doses from 1–200 U daily versus vehicle 
treated controls. Mice treated with a high dose (50–200 U 
daily, red lines) show increased survival by the end of the 
second week of 44.4%, 42.9% and 55.6% respectively while all 
saline treated controls (black dotted line) survive no longer 
than day 11 (p < 0.001). Mice treated with 25 U daily survive 
in 30% (p < 0.001 vs. vehicle). Survival of mice treated with a 
low dose (1–10 U daily) did not show a statistically significant 
increase in survival. Statistical test: log rank statistic for the 
survival curves with pair wise comparison using the Holm-
Sidak method.Malaria Journal 2008, 7:3 http://www.malariajournal.com/content/7/1/3
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while parasitaemia and PCV were not (P = 0.66 and P =
0.74, respectively).
Body temperature
C57BL/6 mice infected with PbA show a characteristic
drop in body temperature when entering the terminal
phase of disease. Data obtained in a typical experiment
are shown in figure 5. The body temperature in the vehicle
treated group dropped suddenly, corresponding to the
onset of severe clinical disease (coma; paraplegia). The
terminal rise of body temperature in two animals coin-
cided with convulsions. Surviving animals in the group
treated with rhEpo 200 U daily on day 4–7 had a similar
drop in body temperature, but they recovered and reached
a stable temperature at the end of the second week
(Figure 5). Those animals died later from anaemia and
hyperparasitaemia.
Gene expression
Gene expression in infected mice was elevated for IL-1β,
TNF, INF-γ (P < 0.001) and Caspase 1 (P < 0.05), but not
for Caspase 3 and LT, compared to uninfected controls.
Treatment with rhEpo was able to decrease this elevation
significantly for IL-1β and TNFα (P < 0.001) and for IFN-
γ (P = 0.001). The treatment does not alter the expression
of LT and the Caspases 1 and 3 (Figure 6).
Apoptotic neurons
Neuronal apoptosis detected by TUNEL staining is a fea-
ture of mice terminal ill with ECM as previously shown
[26]. Comparing the number of apoptotic neurons in the
brains of rhEpo treated mice and vehicle treated controls
with ECM we found a significant decrease in the rhEpo
treated group (Figure 7). Furthermore TUNEL+ showed a
tendency to cluster (Figure 7). RhEpo treatment reduced
the mean number of TUNEL+ neurons counted in sagittal
sections from both brain hemispheres form 197.1 (C.I. of
the mean: 111.7) in vehicle treated animals to 53.1 (C.I.
of the mean: 21.7; P = 0.003).
Mean parasitaemia levels on day 8 Figure 4
Mean parasitaemia levels on day 8. Mean parasiteaemia 
levels on day 8 as percentage of parasitized red blood cells in 
Giemsa-stained smears: The mean values for the different 
groups range from 6.3 – 12.6%. Only the treatment group 
that received recombinant human Erythropoietin 25 U/day 
from day 4–7 (**) was significantly different from the control 
group that had received normal saline (NaCl) (P < 0.05). All 
other differences between the groups were not significant. 
Statistical test: One way ANOVA. Data are presented as 
mean values +/- standard error.
Time depandant increase in survival in recombinant human  erythropoietin-treated mice with cerebral malaria Figure 3
Time depandant increase in survival in recombinant 
human erythropoietin-treated mice with cerebral 
malaria. Time dependant increase in survival in mice with 
CM treated with recombinant human Erythropoietin 
(rhEpo): The cumulative survival analysis of mice ECM 
treated with 100 U daily of rhEpo show increased survival at 
the end of the second week only in mice treated from day 4–
7 (42.9%, p < 0.001 vs. vehicle). The other treatment 
schemes used (day 1–4; day 7–10; day 1–7) and mice that 
received treatment from day 1–7 and where bleed for 10% of 
their total blood volume to prevent excessively high levels of 
packed cell volume did not show a statistically significant 
increase in survival. Statistical test: log rank statistic for the 
survival curves with pair wise comparison using the Holm-
Sidak method.Malaria Journal 2008, 7:3 http://www.malariajournal.com/content/7/1/3
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Discussion
The data presented here demonstrate a protective effect of
rhEpo in ECM in mice with a clear dose and time depend-
ency. animals treated with 50 U to 200 U of rhEpo daily
survive in about half of the cases. Treatment with a low
dose of 1 or 10 IU daily for the same period of time did
not increase survival significantly, while a dose of 25 IU
daily increases survival by about 25%. The dose-depend-
ency was seen in mice treated on day 4–7, while early (day
1–4) and late treatments (day 7–10) were unsuccessful.
Surprisingly, treatment from day 1–7 failed to increase
survival. This failure was in the first place attributed to the
very high packed cell volume (PCV) observed in this
group (mean: 73% on day 8), as a side effect to the treat-
ment with rhEpo. This could have outweighted a possible
positive effect of the treatment. In a subsequent experi-
ment, mice were bled for 150 μl of blood (about 10% of
the total blood volume) on day 5 to prevent excessively
high values for PCV. This intervention lowered the PCV
on day 8 to mean levels equal to those seen in groups
responding to treatment, but not with increased survival.
A blood loss of 10% of the total volume is substantial and
reduces the number of RBC, as well as parasites, thrombo-
cytes and leukocytes, while removing plasma and its con-
tents. However, none of these alterations offer an obvious
explanation for the failure of the treatment from day 1–7.
An early harmful effect of the treatment cannot be
excluded, in line with a study showing that pre-treatment
Body temperature of mice with cerebral malaria Figure 5
Body temperature of mice with cerebral malaria. Vehicle treated mice (left graph) show a characteristic drop of body 
temperature on day 9. Surviving mice in the group treated with recombinant human Erythropoietin 200 U daily on day 4–7 
show a similar drop on day 9–10, but recover afterwards (right graph). The data shown are representative for repeated exper-
iments. The data presented are from one single experiment. Data for the treatment group is representative for mice that 
received rhEpo 50–200 U daily on day 4–5.
Gene expression in the brains of recombinant human eryth- ropoietin-treated and untreated mice with cerebral malaria Figure 6
Gene expression in the brains of recombinant human 
erythropoietin-treated and untreated mice with cer-
ebral malaria. Gene expression in the brains of recom-
binant human erythropoietin-treated and untreated mice 
with cerebral malaria on day 8 relative to uninfected control 
mice (black columns). Increased gene expression in infected 
mice was seen for IL-1β, TNF, INF-γ (P < 0.001) and Caspase 
1 (P < 0.05), but not for LT-α, and Caspase 3. Gene expres-
sion for the IL-β, TNF and INF-γ was significantly reduced in 
rhEpo treated mice (P < 0.001). The treatment does not 
alter the expression of LT-α and the Caspases 1 and 3. Statis-
tical test: Two way ANOVA. Values are presented as mean 
values relative to uninfected controls. Error bars: Standard 
deviation (** = P < 0.001).Malaria Journal 2008, 7:3 http://www.malariajournal.com/content/7/1/3
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with Epo of C57BL/6 infected with Plasmodium chabaudi
can induced 100% mortality in mice with an otherwise
self-limiting course of the disease [27].
The histo-pathological correlate of the neurological dys-
function and sequelae in CM is not known. Axonal injury
has been proposed to play a role [28] as well as apoptotic
cell death of neurons in ECM in a clustered manner [26].
A recent study by Kaiser et al described this pattern only in
rhEpo-treated mice, but not in untreated animals with
ECM [22]. In our hands both rhEpo-treated mice and
untreated mice with ECM develop neuronal apoptosis in
this typical clustered manner, while the numbers of
TUNEL+ cells as well as the number of clusters in treated
animals is reduced (Figure 7). As TUNEL+ neurons are a
feature of the very late stage of ECM [26], a possible expla-
nation for this discrepancy between the results presented
here and those of Kaiser et al could, therefore, be found in
the different time points for killing due to different sur-
vival times of treated and untreated animals in their study.
Systemic administration of rhEpo has been shown to pre-
vent apoptotic cell death in an animal model of stroke
[11], an effect which is likely to be the basis of the reduced
infarct size and improved clinical outcome in human
stroke patients treated with high dose rhEpo [23]. Accord-
ingly, the present study demonstrated that rhEpo treat-
ment, in addition to increasing survival in mice with
ECM, prevents neuronal apoptosis in the CNS. As the
Epo-R has been detected on neurons [29], the neuropro-
tective effect could be due to a direct effect of rhEpo. The
data presented here also showed a reduced inflammatory
response in the CNS of rhEpo treated mice, as indicated by
reduced gene expression of proinflammatory cytokines in
the brain tissue; an improved inflammatory response in
the brain could contribute to neuroprotection. Further
studies are required to determine the sequence of events.
To identify possible pathways leading to apoptosis in
ECM, the expression of caspase 3 in the brain was studied.
Caspase 3 is involved in signalling pathways leading to
apoptosis [30]. It has previously been shown that immu-
noreactivity for cleaved (i.e. activated) caspase 3 is
increased in brains of mice with ECM [26], without a top-
ographical association with TUNEL+ neurons. The gene
expression of caspase 3 was not increased in ECM and was
Treatment with recombinant human erythropoietin in mice with cerebral malaria reduces neuronal apoptosis in the brain Figure 7
Treatment with recombinant human erythropoietin in mice with cerebral malaria reduces neuronal apoptosis 
in the brain. Apoptotic neurons in the brain of mice with ECM. The micrograph shows TUNEL (Terminal deoxynucleotidyl 
transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-digoxigenin nick end labelling) positive nuclei of cells in the cor-
tex of a terminally ill mouse with ECM. Earlier work had shown that the round shaped nuclei belong to neurons [24]. The 
mean number of TUNEL+ neurons in the brains of recombinant human Erythropoietin (rhEpo) treated mice with ECM is sig-
nificantly lower than in vehicle treated controls (P = 0.006). Countings from TUNEL-stained sagittal sections of both hemi-
spheres. Scale bar: 50 μm. Statistical analysis: Students t-test. The ends of the boxes define the 25th and 75th percentiles, with 
a line at the median and error bars defining the 5th and 95th percentiles.Malaria Journal 2008, 7:3 http://www.malariajournal.com/content/7/1/3
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independent of rhEpo treatment, indicating that they are
possibly not involved in the induction of apoptosis in
ECM. However, the induction of apoptosis in ECM might
as well have been induced by caspase-independent path-
ways (reviewed in [30,31]). As caspase 3 is activated by
enzymatic cleavage, increased gene expression might not
be needed.
The expression of IL-1β, TNF and INF-γ mRNA in the
brains increased during ECM, and this increase was
reduced by rhEpo treatment (Figure 6). The data for TNF
and INF-γ are in line with previous findings [22], and
together this current findings for IL-1β clearly indicate
that rhEpo-treatment can ameliorate the inflammatory
process in ECM. However, the results for LT are surprising:
Engwerda et al had pointed at the importance of LT, as
C57BL/6 mice deficient for LT-α are resistant to CM [32].
In an elegant study, they showed that brain cells are cru-
cial producers of LT-α and proposed endothelial cells,
astrocytes or microglia as possible source [32], while Rae
et al reported a 3–4-fold up-regulation of LT mRNA in the
brain of mice with CM [33]. Nevertheless, here LT mRNA
levels were not increased in ECM compared to uninfected
controls. Adding these findings to the findings of Eng-
werda et al, LT appears to be necessary for the patho-
mechanism of ECM, but probably not as a factor trigger-
ing cerebral pathology. Treatment with rhEpo had no sig-
nificant influence on levels of LT expression (P = 0.08),
but the power of the test was too low to reject the possibil-
ity completely.
The means by which rhEpo treatment may influence the
inflammatory response in the CNS remain unclear. It is
unlikely that increased levels of PCV are essential, if
involved at all, as the induction of erythopoiesis in the dif-
ferent treatment groups did not correlate with increased
survival. Even the lowest dose, 1 U daily, had significant
erythropoietic effect, and 10 U daily resulted in a maximal
induction, not further amplified by higher doses (Figure 1
and 3). By contrast, a dose of 25 U/day rhEpo was neces-
sary to increase survival, with maximal effect when the
mice were treated with 50 U to 200 U. The results of the
statistical modelling with the Cox regression model
clearly support this interpretation, as it detects treatment,
but not PCV nor parasitaemia as significantly associated
with increased survival. The protective effect of rhEpo in
murine CM appears, therefore, to be independent from its
haematopoietic effect.
The data on body temperature indicate that the effect of
the treatment was via reduced severity as well as delayed
course of disease: Surviving animals in the treatment
group showed a later, but equal drop in body temperature
as vehicle treated mice, before returning to values close to
normal (Figure 5). RhEpo treatment in ECM seems to
work before, as well as during severe disease. This is of
importance as the main target group for a proposed
adjunct treatment in CM is patients already having devel-
oped signs of severe disease. Marsh et al have previously
reported a distinct distribution of CM and severe malaria
anaemia (SMA), with respect to age, in children present-
ing to a hospital in Kilifi, Kenya [34]. Most cases of SMA
appear within the first two years of age, while the peak of
CM is in the age group 3–4 years. Having these current
findings of the neuro-protective effect of Epo and the fact
that endogenous Epo levels are high in children with SMA
in mind, it can be proposed that these increased levels of
endogenous Epo in very young children could contribute
to this apparent dichotomy, by protecting against CM.
Conclusion
RhEpo increased survival in ECM in a dose-dependent
manner, was able to reduce the inflammatory response in
the brain, and protected functional brain tissue by reduc-
ing neuronal apoptosis. It has, therefore, the potential to
become a candidate for adjunct treatment of CM in
humans, in particular when seen in the light of its excel-
lent safety profile: for decades rhEpo has been used for
long term therapy of chronic renal failure. Given in a
weekly dose of 50–150 U/kg, it has been shown to be safe
for extended periods with rare adverse events (for review
see [35]) and experience gained from studies in pre-term
infants shows that doses of 2,100 U/week are safe in very
young children [36-38]. Furthermore, rhEpo given in a
neuroprotective dose of 33,000 IU to stroke patients
proved recently to be safe and well-tolerated [23]. Peak
plasma concentrations of rhEpo in these patients, as well
as in healthy volunteers receiving 2,400 IU/kg rhEpo did
not exceed levels of endogenous Epo that can be meas-
ured in severely anaemic patients with normal kidney
function [7,23,39]. Carefully controlled studies are now
indicated and required to proof the concept in humans,
including on the timing and the duration of Epo injection.
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